AngioDynamics Inc (ANGO) reports an 8.8% revenue increase and raises full-year guidance amid robust Med Tech performance and ...

CPT I code for NanoKnife prostate procedures is set to take effect on January 1, with management expecting incremental, ...

AngioDynamics, Inc. ANGO reported breakeven adjusted earnings per share for second-quarter fiscal 2026, marking an ...

AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and ...

Earnings call AngioDynamics reported Q2 FY25 revenue of $73M, up 9.2% YoY, led by 25% MedTech growth. Adjusted EBITDA reached $3.1M, reversing a loss from last year. Management raised MedTech growth ...

CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...

TCT 176: Randomized comparison of intracoronary lithotripsy and rotational atherectomy for the treatment of severely calcified vessels – ROTA.shock trial Receive the the latest news, research, and ...

TCT 779: Comparison Between Transcatheter Edge-to-Edge Repair and Mitral Valve Replacement in Acute Heart Failure: A Nationwide Study Receive the the latest news, research, and presentations from ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Total Worldwide Revenue: $73 million, growth of approximately 9% year-over-year. MedTech Segment Revenue: $31.6 million, a 25% year-over-year increase. Mechanical Thrombectomy Revenue: Increased 46.2% ...